Workflow from Scientific Research

AURORA Trial schema. Patients with histologically confirmed metastatic breast cancer (MBC) were eligible, regardless of hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) status. Patients were randomized 1:1 to receive either a CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) or ET alone. Circulating tumor cells (CTCs) were enumerated at baseline, during treatment and at disease progression. Circulating tumor DNA (ctDNA) was collected at baseline, during treatment, at disease progression and every 3 months after progression.

DOI